UR igem wiki



Our team decided to use synthetic biology to create an inexpensive production method of monoclonal antibodies. This form of production can help increase the accessibility of immunoassays to a variety of healthcare situations, as cost and local availability can be a large barrier in patient care in rural or less developed nations (Buzza et al., 2011). Using Escherichia coli (E. coli) to produce antibodies offers a great alternative to traditional antibody production because of its reduced production costs and lack of reliance on animal models. Additionally, our proposed monoclonal antibodies, for employment in our lateral flow assay, are all molecules that have been FDA-approved for immunotherapy options for other conditions (Sarosiek et al., 2016). This provides an additional use of our monoclonal antibodies beyond that of their use as detecting molecules in immunoassays. We hope that in the future, these bacterially-produced antibodies can be approved for the detection and treatment of endometriosis. Synthetically-derived antibodies can lead the way to an inexpensive, personalized medicine approach that can be available locally tol patients. All BioBricks we designed were optimized for use in E. coli using Reverse Translate Sofware from The Sequence Manipulation Suite.

  • Parts Table
  • Name Type Description Designer Length
    BBa_K3346000 Coding Siltuximab Heavy Variable Chain for IgG Emily Laskey 328
    BBa_K3346001 Coding Siltuximab Light Chain for IgG Emily Laskey 978
    BBa_K3346002 Coding Murine Constant Chain for IgG Expression Emily Laskey 1362
    BBa_K3346003 Coding Siltuximab Full Length IgG Emily Laskey 2698
    BBa_K3346004 Coding Anti-Estradiol Fab Fragment Emily Laskey 1523
    BBa_K3346005 Coding Anionic Peptide Tag for Therapeutic Transport of Antibodies Emily Laskey 489
    BBa_K3346006 Coding Anti-Estradiol Fab Fragment with Anionic Peptide Tag for Drug Delivery Emily Laskey 2018
    BBa_K3346011 Signalling ERE Based Estrogen Biosensor Circuit Gabe Isaacson 884


    Buzza, C., Ono, S. S., Turvey, C., Wittrock, S., Noble, M., Reddy, G., Kaboli, P. J., & Reisinger, H. S. (2011). Distance is Relative: Unpacking a Principal Barrier in Rural Healthcare. Journal of General Internal Medicine, 26(S2), 648–654.

    Sarosiek, S., Shah, R., & Munshi, N. C. (2016). Review of siltuximab in the treatment of multicentric Castleman’s disease. Therapeutic Advances in Hematology, 7(6), 360–366.